Cargando…
The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors
Identification of novel tumor-specific targets is important for the future development of immunotherapeutic strategies using genetically engineered T cells or vaccines. In this study, we characterized the expression of VCX2, a member of the VCX/Y cancer/testis antigen family, in a large panel of nor...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900521/ https://www.ncbi.nlm.nih.gov/pubmed/33634013 http://dx.doi.org/10.3389/fonc.2020.584024 |
_version_ | 1783654223770025984 |
---|---|
author | Jakobsen, Mie K. Traynor, Sofie Stæhr, Mette Duijf, Pascal G. Nielsen, Aaraby Y. Terp, Mikkel G. Pedersen, Christina B. Guldberg, Per Ditzel, Henrik J. Gjerstorff, Morten F. |
author_facet | Jakobsen, Mie K. Traynor, Sofie Stæhr, Mette Duijf, Pascal G. Nielsen, Aaraby Y. Terp, Mikkel G. Pedersen, Christina B. Guldberg, Per Ditzel, Henrik J. Gjerstorff, Morten F. |
author_sort | Jakobsen, Mie K. |
collection | PubMed |
description | Identification of novel tumor-specific targets is important for the future development of immunotherapeutic strategies using genetically engineered T cells or vaccines. In this study, we characterized the expression of VCX2, a member of the VCX/Y cancer/testis antigen family, in a large panel of normal tissues and tumors from multiple cancer types using immunohistochemical staining and RNA expression data. In normal tissues, VCX2 was detected in the germ cells of the testis at all stages of maturation but not in any somatic tissues. Among malignancies, VCX2 was only found in tumors of a small subset of melanoma patients and thus rarely expressed compared to other cancer/testis antigens such as GAGE and MAGE-A. The expression of VCX2 correlated with that of other VCX/Y genes. Importantly, we found that expression of VCX2 was inversely correlated with promoter methylation and could be activated by treatment with a DNA methyltransferase inhibitor in multiple breast cancer and melanoma cell lines and a breast cancer patient-derived xenograft. The effect could be further potentiated by combining the DNA methyltransferase inhibitor with a histone deacetylase inhibitor. Our results show that the expression of VCX2 can be epigenetically induced in cancer cells and therefore could be an attractive target for immunotherapy of cancer. |
format | Online Article Text |
id | pubmed-7900521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79005212021-02-24 The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors Jakobsen, Mie K. Traynor, Sofie Stæhr, Mette Duijf, Pascal G. Nielsen, Aaraby Y. Terp, Mikkel G. Pedersen, Christina B. Guldberg, Per Ditzel, Henrik J. Gjerstorff, Morten F. Front Oncol Oncology Identification of novel tumor-specific targets is important for the future development of immunotherapeutic strategies using genetically engineered T cells or vaccines. In this study, we characterized the expression of VCX2, a member of the VCX/Y cancer/testis antigen family, in a large panel of normal tissues and tumors from multiple cancer types using immunohistochemical staining and RNA expression data. In normal tissues, VCX2 was detected in the germ cells of the testis at all stages of maturation but not in any somatic tissues. Among malignancies, VCX2 was only found in tumors of a small subset of melanoma patients and thus rarely expressed compared to other cancer/testis antigens such as GAGE and MAGE-A. The expression of VCX2 correlated with that of other VCX/Y genes. Importantly, we found that expression of VCX2 was inversely correlated with promoter methylation and could be activated by treatment with a DNA methyltransferase inhibitor in multiple breast cancer and melanoma cell lines and a breast cancer patient-derived xenograft. The effect could be further potentiated by combining the DNA methyltransferase inhibitor with a histone deacetylase inhibitor. Our results show that the expression of VCX2 can be epigenetically induced in cancer cells and therefore could be an attractive target for immunotherapy of cancer. Frontiers Media S.A. 2021-02-09 /pmc/articles/PMC7900521/ /pubmed/33634013 http://dx.doi.org/10.3389/fonc.2020.584024 Text en Copyright © 2021 Jakobsen, Traynor, Stæhr, Duijf, Nielsen, Terp, Pedersen, Guldberg, Ditzel and Gjerstorff http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Jakobsen, Mie K. Traynor, Sofie Stæhr, Mette Duijf, Pascal G. Nielsen, Aaraby Y. Terp, Mikkel G. Pedersen, Christina B. Guldberg, Per Ditzel, Henrik J. Gjerstorff, Morten F. The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors |
title | The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors |
title_full | The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors |
title_fullStr | The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors |
title_full_unstemmed | The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors |
title_short | The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors |
title_sort | cancer/testis antigen gene vcx2 is rarely expressed in malignancies but can be epigenetically activated using dna methyltransferase and histone deacetylase inhibitors |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900521/ https://www.ncbi.nlm.nih.gov/pubmed/33634013 http://dx.doi.org/10.3389/fonc.2020.584024 |
work_keys_str_mv | AT jakobsenmiek thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT traynorsofie thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT stæhrmette thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT duijfpascalg thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT nielsenaarabyy thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT terpmikkelg thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT pedersenchristinab thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT guldbergper thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT ditzelhenrikj thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT gjerstorffmortenf thecancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT jakobsenmiek cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT traynorsofie cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT stæhrmette cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT duijfpascalg cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT nielsenaarabyy cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT terpmikkelg cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT pedersenchristinab cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT guldbergper cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT ditzelhenrikj cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors AT gjerstorffmortenf cancertestisantigengenevcx2israrelyexpressedinmalignanciesbutcanbeepigeneticallyactivatedusingdnamethyltransferaseandhistonedeacetylaseinhibitors |